AU612575B2 - Interleukin-2 induced antineoplastic peptide - Google Patents

Interleukin-2 induced antineoplastic peptide Download PDF

Info

Publication number
AU612575B2
AU612575B2 AU73780/87A AU7378087A AU612575B2 AU 612575 B2 AU612575 B2 AU 612575B2 AU 73780/87 A AU73780/87 A AU 73780/87A AU 7378087 A AU7378087 A AU 7378087A AU 612575 B2 AU612575 B2 AU 612575B2
Authority
AU
Australia
Prior art keywords
cells
antineoplastin
inhibiting
proliferation
neoplastic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU73780/87A
Other languages
English (en)
Other versions
AU7378087A (en
Inventor
Ingegerd Hellstrom
Karl Erik Hellstrom
Daniel R. Twardzik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU7378087A publication Critical patent/AU7378087A/en
Application granted granted Critical
Publication of AU612575B2 publication Critical patent/AU612575B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4718—Cytokine-induced proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/91—Cell lines ; Processes using cell lines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU73780/87A 1986-06-04 1987-06-03 Interleukin-2 induced antineoplastic peptide Ceased AU612575B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87044086A 1986-06-04 1986-06-04
US870440 1986-06-04

Publications (2)

Publication Number Publication Date
AU7378087A AU7378087A (en) 1987-12-10
AU612575B2 true AU612575B2 (en) 1991-07-18

Family

ID=25355375

Family Applications (1)

Application Number Title Priority Date Filing Date
AU73780/87A Ceased AU612575B2 (en) 1986-06-04 1987-06-03 Interleukin-2 induced antineoplastic peptide

Country Status (9)

Country Link
EP (1) EP0248642B1 (enExample)
JP (1) JPS6322100A (enExample)
AT (1) ATE81591T1 (enExample)
AU (1) AU612575B2 (enExample)
CA (1) CA1320906C (enExample)
DE (1) DE3782276T2 (enExample)
ES (1) ES2052562T3 (enExample)
GR (1) GR3006212T3 (enExample)
IL (1) IL82734A (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1196958B (it) * 1986-07-10 1988-11-25 Ellem Ind Farmaceutica Derivato di timo attivo per via orale, procedimenti per la sua preparazione e relative composizioni farmaceutiche
AU609128B2 (en) * 1987-04-02 1991-04-26 Amrad Operations Pty. Limited Leukaemia-inhibitory factor
JP7268039B2 (ja) 2018-02-01 2023-05-02 エヌケーマックス カンパニー リミテッド がん治療のためのナチュラルキラー細胞および組成物の製造方法

Also Published As

Publication number Publication date
GR3006212T3 (enExample) 1993-06-21
ES2052562T3 (es) 1994-07-16
DE3782276T2 (de) 1993-03-04
EP0248642A3 (en) 1989-11-02
EP0248642A2 (en) 1987-12-09
ATE81591T1 (de) 1992-11-15
AU7378087A (en) 1987-12-10
JPS6322100A (ja) 1988-01-29
DE3782276D1 (de) 1992-11-26
CA1320906C (en) 1993-08-03
IL82734A0 (en) 1987-12-20
EP0248642B1 (en) 1992-10-21
IL82734A (en) 1992-05-25

Similar Documents

Publication Publication Date Title
Ferreira et al. Activity of various fractions of bradykinin potentiating factor against angiotensin I converting enzyme
Alford et al. Delayed cutaneous hypersensitivity reactions to extracts of malignant and normal breast cells
JP3213942B2 (ja) ヒトの治療に有用なポリペプチド性物質
CA2186423C (en) Protein which induces interferon-gamma production by immunocompetent cell
Balcewicz-Sablinska et al. Human eosinophil cytotoxicity-enhancing factor. II. Multiple forms synthesized by U937 cells and their relationship to thioredoxin/adult T cell leukemia-derived factor
EP2189470A1 (en) Tumor antigens
US5837248A (en) Peptide capable of inducing immune response to human gastric cancer and agent for preventing or treating human gastric cancer, containing the peptide
JP2001525337A (ja) 前立腺癌の治療に有効なコンジュゲート
US5393534A (en) Liver-derived tumor cell growth inhibitor
Kamiyama et al. Studies on the structure of α1-acid glycoprotein II. Preparation and characterization of a glycopeptide fraction
AU612575B2 (en) Interleukin-2 induced antineoplastic peptide
CN102133233B (zh) 一种具有抗肿瘤活性的蜈蚣提取物及其制备方法
US5114926A (en) Tetrapeptide inhibiting the entry into cycle of hemopoietic stem cells processes for its preparation, and its uses
RU2205010C2 (ru) Природные противоопухолевые или противовирусные вещества и их применение
Park et al. Isolation and characterization of lectins from stem and leaves of Korean mistletoe (Viscum album var. coloratum) by affinity chromatography
CN115006425A (zh) 血满草酸性多糖在制备免疫调节和肿瘤治疗药物中的用途
CN112979640B (zh) 一类生物碱二聚体类化合物及其在制备pd-1/pd-l1通路抑制剂中的应用
IE861095L (en) Preparing recombinant interferon
RU2593003C2 (ru) Препарат экзосом - онкосом и способ иммунотерапии солидных опухолей с его использованием
SU710503A3 (ru) Способ получени ацетилированных водорастворимых экстрактов, обладающих иммуностимулирующим действием
EP0086475A2 (en) A method of manufacturing anti-tumor substances
US4752578A (en) Collagenase inducing factor
GB2185485A (en) Cell growth regulatory factor
JP4914350B2 (ja) セラリシン（Ｓｅｒｒａｌｉｓｉｎｓ）のポリペプチド断片を含む医薬組成物
Wang et al. Antitumor effects of the molecule-downsized immunoconjugate composed of lidamycin and Fab’fragment of monoclonal antibody directed against type IV collagenase